SBIR/STTR Research Award

Compositions for Prevention/Prophylactic Treatment of Poison Ivy Dermatitis

Award identifier f9902d2cd0e3e9224fd836869c61248959ad9c84db632565b15b729e029d1955Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,074

Program and phase

SBIR · Phase I

Award year

2006

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ElSohly Laboratories, Incorporated
Proposal award date
Not reported
Contract end date
Not reported
UEI
SQB7R3XYCW35
Solicitation number
PHS2006-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The long term objectives of this proposal are aimed at the development of new composition(s) to be used for the prophylactic treatment/prevention of poison ivy contact dermatitis in sensitive individuals. Poison ivy/poison oak and another related species poison sumac are the main cause of occupational hazards for outdoor workers in the United States. Most of the products on the market today are aimed at applying a chemical barrier prior to being exposed to these plants or directed toward symptomatic treatment of the dermatitis. The products proposed in this application will be directed towards treatment of individuals who have never been exposed to poison ivy and therefore inducing tolerance in these individuals (equivalent to immunization) and/or towards prophylactic treatment of already sensitive individuals, perhaps using a single injection prior to each season. The aims, therefore of this proposal will be to prepare (synthesize) different derivatives with enhanced physical and formulation characteristics, testing of these products (or at least one selected agent) in the guinea pig animal model for efficacy as a proof of concept. The results of this work will form the basis for a Phase II application directed toward optimization of formulation, dosage and route of administration as well as carrying out stability, pharmacokinetics and preclinical toxicology/developmental activities. This proposal addresses a major public health problem, namely contact allergic dermatitis and promises the development of an effective agent to address this problem.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

17 SBIR/STTR records share this UEI (1986–2019). Reported award amounts total $4,150,945. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.